Search
Humacyte Inc
HUMAAdd to Watchlist
0.642USD
-0.039-5.73%
Close 08-21 16:00（ET）
178.62MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-21The current earnings forecast score of Humacyte Inc is 8.00, ranking 168 out of 377 in the Biotechnology & Medical Research industry. The average price target is 3.50, with a high of 25.00 and a low of 3.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
1.850
Target Price
+171.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Humacyte Inc
HUMA
5
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Humacyte Inc's expected revenue for the next quarter?
Humacyte Inc's expected revenue is 1.36M.
What is Humacyte Inc's price target?
Analysts forecast that Humacyte Inc's price target is USD 3.50, with the highest forecast at USD 25.00 and the lowest forecast at USD 3.00.
How have Humacyte IncHUMA's recent earnings per share performed?
The market expectation was USD -0.16, while Humacyte IncHUMA's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Humacyte Inc?
Based on the ratings of Humacyte Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.